TNDM
Tandem Diabetes Care, Inc. Healthcare - Medical Devices Investor Relations →
Tandem Diabetes Care, Inc. (TNDM) closed at $24.82 as of 2026-03-20, trading 22.9% below its 200-week moving average of $32.18. This places TNDM in the extreme value zone. The stock moved further from the line this week, up from -33.4% last week. The 14-week RSI sits at 59, indicating neutral momentum.
Over the past 14 weeks, up-weeks have carried more volume than down-weeks (2.14 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.
Over the past 596 weeks of data, TNDM has crossed below its 200-week moving average 2 times. On average, these episodes lasted 214 weeks. The average one-year return after crossing below was -47.3%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $1696 million, TNDM is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -97.9%. The stock trades at 10.9x book value.
Share count has increased 5.9% over three years, indicating dilution.
Over the past 11.5 years, a hypothetical investment of $100 in TNDM would have grown to $16, compared to $390 for the S&P 500. TNDM has returned -15.0% annualized vs 12.6% for the index, underperforming the broader market over this period.
Free cash flow has been declining at a -100% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: TNDM vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After TNDM Crosses Below the Line?
Across 2 historical episodes, buying TNDM when it crossed below its 200-week moving average produced an average return of -52.5% after 12 months (median -44.0%), compared to +4.0% for the S&P 500 over the same periods. After 24 months, the average return was -53.5% vs +21.0% for the index.
Each line shows $100 invested at the moment TNDM crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
TNDM has crossed below its 200-week MA 2 times with an average 1-year return of +-47.3% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Oct 2014 | Feb 2019 | 225 | 97.7% | -47.3% | -83.5% |
| May 2022 | Ongoing | 203+ | 81.5% | Ongoing | -67.3% |
| Average | 214 | — | +-47.3% | — |
Frequently Asked Questions
Is TNDM below its 200-week moving average?
Yes. As of 2026-03-20, Tandem Diabetes Care, Inc. (TNDM) is trading 22.9% below its 200-week moving average of $32.18. The current price is $24.82.
What is TNDM's 200-week moving average price?
Tandem Diabetes Care, Inc.'s 200-week moving average is $32.18 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when TNDM drops below its 200-week moving average?
TNDM has crossed below its 200-week moving average 2 times in our data. The average one-year return after these crossings was -47.3%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 214 weeks on average.
Is TNDM a good value right now?
Here's what our data says about TNDM as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 59. Free cash flow is currently negative. Return on equity is -97.9%. Price-to-book is 10.9x. This is not a buy or sell recommendation — always do your own research.
How does TNDM compare to the S&P 500?
Over the past 11.5 years, $100 invested in TNDM would have grown to $16, compared to $390 for the S&P 500. That's -15.0% annualized vs 12.6% for the index. TNDM has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20